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Hymenoptera venom allergy (HVA) represents a particular risk for exceptionally severe anaphylactic sting reactions
in patients with clonal mast cell disorders (CMD). Nevertheless, conventional investigations are not sufficient to do
accurate risk assessments. Increased levels of baseline serum tryptase (sBT) (>11.4 μg/L) is highly associated with
severe anaphylactic reactions and with a possible underlying CMD. The measurement of baseline serum tryptase,
thus, has opened the possibility to screen for CMD. In the present study, we sought to investigate whether bone
marrow evaluation provides more accurate diagnosis in patients with HVA.
Three patients of the same sex and similar age with HVA were enrolled in this clinical study. The patients
underwent comprehensive allergy work-up including skin prick testing, measurements of serum total IgE
concentrations and baseline serum tryptase. Bone-marrow biopsies were also performed in all three patients to
assess underlying CMD.
We evaluated characteristics of the bone marrow mast cells by pathology, flow cytometry and detection of D816V
mutation by using current WHO-criteria, which led to changes in the final diagnosis compared to the assessments
done by classical allergy work-up and measurements of sBT. Three distinct diagnostic outcomes including systemic
mastocytosis, monoclonal mast cell activation syndrome and non-clonal HVA were revealed.
We conclude that a bone marrow investigation is required for the correct diagnosis of hymenoptera venom-
induced anaphylactic reactions in patients with elevated baseline tryptase levels (>11.4 μg/L), and this has
important implications for management strategies.
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be severe and potentially fatal. The special association
between hymenoptera venom allergy (HVA) and
mastocytosis has been long observed [1,2]. This concept
has been broadened during recent years to encompass
the larger disease entity of clonal mast cell disorders
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been reported [4,5].
The term CMD comprises systemic mastocytosis (SM)
and monoclonal mast cell activation syndrome (MMAS)
[6-8]. The common finding in these two conditions is
the mast cells clonality; which can be proven by the de-
tection of a codon 816 KIT mutation and/or occurrence
of immunophenotypically aberrant mast cells expressing
CD2 and/or CD25 [7,8]. In patients with MMAS, the
WHO criteria for systemic mastocytosis are not met.
Nevertheless, by using methods with higher sensitivity to
detect bone marrow mast cells at low frequencies, and
the KIT mutation analysis of purified mast cells could
further improve the diagnosis [9].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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history, skin prick test and allergen-specific IgE [10].
Moreover, the measurement of baseline serum tryptase
(sBT) has opened the possibility to screen for CMD.
However, conventional investigations, including allergy
work-up and measurements of sBT levels, are not suffi-
cient enough to predict a possible underlying CMD. In
the present study, therefore, we sought to assess whether
investigation with bone marrow biopsy and flow cytome-
try provides more accurate diagnosis in HVA patients
with elevated baseline tryptase levels (>11.4 μg/L).
Findings
Patients and methods
Case 1: A 72 year old, previously healthy woman without
known sensitization, had a wasp sting on her hand in
2001. She reacted only with local swelling. She got an-
other wasp sting on her lower arm in 2003, and immedi-
ately noted swelling of the face. She felt tingling in hands
and fingers, laid down on the ground and began to sweat.
She had no breathing difficulties. She was about to pass
out when the ambulance arrived. Her blood pressure was
too low to measure. The patient received standard treat-
ment with epinephrine and intravenous fluids by ambu-
lance personal before she was transferred to hospital,
where she remained overnight and recovered.
Case 2: A 67 year old, previously healthy woman with-
out known sensitization, got a wasp sting in her lower
leg during the 1970s and reacted only with local swelling.
In 2005 she had another wasp sting on her left elbow.
Within 5 minutes, she became dizzy and experienced pal-
pitations and chills, and had abdominal cramps, nausea
and vomiting. Shortly thereafter she became unconscious
and suffered urinary and fecal incontinence. She was
transferred to hospital by ambulance, where she received
standard treatment with epinephrine, antihistamines and
corticosteroids and recovered.
Case 3: A 71 year old, previously healthy woman had
her first wasp sting at the age of 5. She passed out and
was taken into hospital. During the 1970s, she received
another wasp sting and again reacted with syncope. She
was transferred to the local hospital and received treat-
ment with epinephrine, antihistamines and corticoste-
roids before she recovered. More recently, in 2008, she
became dizzy and had heart palpitations after yet another
wasp sting. She also had breathing difficulties. She was
afraid of treating herself with epinephrine autoinjector be-
cause of concern about its side effects, but after a couple
of hours she recovered spontaneously.
All patients went through a complete clinical and phys-
ical examination along with an allergic work-up including
skin prick testing (SPT) with commercial extracts (ALK-
Abelló A/S, Horsholm, Denmark) of hymenoptera venom
(honey bee and vespula). SPT was considered positive ifthe difference between the mean of the wheal's length and
width and the negative control was at least 3 mm. The
specific IgE antibody test (Immuno CAP Phadiatop®,
ThermoFisher, Uppsala, Sweden) was also performed and
considered positive for values ≥0.35 kU/L. Moreover,
serum concentrations (μg/L) of baseline tryptase levels
(ThermoFisher) and serum total IgE (kU/L) levels were
determined by ImmunoCap Total IgE (ThermoFisher,
Uppsala, Sweden) in all three patients according to manu-
facturer’s instructions.
In the third case, we have further investigated by
component-resolved diagnosis of serum sIgE antibodies
with purified and recombinant species-specific allergens
of hymenoptera venom r Ves v1, r Ves v5 and r Api m1
IgE (ThermoFisher, Uppsala, Sweden). The presence of
hymenoptera allergen through basophil allergen thresh-
old sensitivity, CD-sens, was also performed by using
commercial honey bee and vespula extracts (ALK-
Abelló A/S, Horsholm, Denmark), as previously de-
scribed [11]. Finally, intracutaneous tests (ICT) were
performed using bee and vespid venom extracts (ALK-
Abelló A/S, Horsholm, Denmark). A volume of 0.02 ml
of allergen concentrations ranging from 10-5 - 10° μg/ml,
as well as negative and positive control (histamine 0.1mg/
ml) were administered simultaneously in the skin. A wheal
of 5 mm in diameter with erythema after 15 min was
regarded as a positive reaction [12].
Diagnosis of anaphylaxis was confirmed in all patients
according to NIH criteria [13], when either reduced
blood pressure or associated-symptoms like syncope/
pre-syncope; and/or respiratory compromise or a laryn-
geal oedema were present accompanied by the involve-
ment of the skin-mucosal tissue or gastrointestinal
symptoms.
Mast cells in bone marrow biopsy sections were ana-
lyzed to evaluate underlying CMD following established
criteria for morphology, histology and immunohistochem-
istry, flow cytometry, and mutational analysis [14-16].
Diagnosis of systemic mastocytosis was evaluated using
current WHO criteria [6] (Table 1). Notably, none of the
patients presented with urticaria pigmentosa (UP) like
skin lesions.
The study was approved by Stockholm's Ethical Review
Board, (Dnr: 2011/1750-31/3), and patients provided their
informed consent.Results
Both SPT and specific IgE antibody test by ImmunoCAP
were positive in Case 1 and 2. Nevertheless, in Case 3,
SPT, ImmunoCAP, component-resolved analysis of hy-
menoptera venom r Ves v1, r Ves v5 and r Api m1 IgE
(<0.10 kE/L), and also basophil activation test CD-sens
for hymenoptera venom were all negative (<0.10 kE/L).
Table 1 WHO diagnostic criteria for systemic
mastocytosis*
Major criterion
1. Presence of multifocal, dense mast cell infiltrates (>15 in aggregates)
in bone marrow or other extracutaneous organs
Minor criteria
1. >25% mast cells spindle-shaped or with abnormal morphology in
bone marrow or other extracutaneous organs.
2. Detection of c-kit point mutation at codon 816 in bone marrow,
blood or extracutaneous organs
3. Mast cells that coexpress CD117 with CD2 and/or CD25, in bone
marrow or extracutaneous organs
4. Persistent increased serum total tryptase level (>20 ng/ml)
*The diagnosis of systemic mastocytosis (SM) can be established if the major
and one minor criterion or three minor criteria are fulfilled (adapted from
reference 6). If the patients fulfill only one or two minor criteria (particularly
criteria 2 or 3), which not sufficient for SM diagnosis, will be diagnosed as
monoclonal mast cell activation syndrome.
Figure 1 Flow cytometric analysis of bone marrow aspirates in three
multiparameter flow cytometry. The percentages of CD117++/CD33+ mast
CD33+/CD25+/CD2+ in the three cases are indicated in the graph. In case
divided, based on expression of CD25 and CD2 in two populations; norma
of CD25 (green) and CD2 (blue) (0.11%). In case 2, total mast cells were 0.0
frequency of mast cells was below the detection limit. The antibody comb
(PerCP-Cy5.5; Becton-Dickinson) - CD34 (PC7; Beckman-Coulter) - CD117 (A
(Krome Orange; Beckman-Coulter). 500 000 cells were collected using a Ca
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reaction for wasp venom at concentration of 10-4 μg/ml.
Histopathological, immunohistochemical and flow cy-
tometry investigation of bone marrow led to changes in
the final diagnosis compared to the assessments done by
classical allergy work-up and measurements of serum
baseline tryptase (sBT), and three distinct diagnostic
outcomes were associated with the HVA. The MMAS
diagnosis was made in Case 1 since only 2 minor criteria
was fulfilled (aberrant phenotype and KIT D816V muta-
tion); whereas Case 2 received diagnosis of SM by fulfill-
ment of 3 minor criteria (atypical mast cell morphology,
aberrant phenotype and Kit D816V mutation). However,
there were no signs of mast cell clonality in Case 3.
Figure 1 and Table 2 summarizes the different features
of the patients.cases. The mast cell frequency and phenotype as evaluated by
cells and of mast cells with aberrant phenotype CD117++/
1, 0.27% of total bone marrow cells were mast cells. These could be
l mast cells (pink) (0.16%) and pathological mast cells with expression
9% and the majority of these were CD25+/CD2+ (0.08%). In case 3, the
ination used was CD2 (FITC; DAKO) - CD25 (PE; DAKO) - CD33
PC; Beckman-Coulter) – HLA-DR (Pacific Blue; BioLegend) – CD45
nto2 flow cytometer (BD Bioscience).
Table 2 Summary of the investigations and demographic and clinical characteristics of patients
Case No 1 2 3
Gender Female Female Female
Current age (age with latest reaction) 72 (63) 67 (60) 71 (67)
Cause of anaphylaxis Wasp Wasp Wasp
Symptoms during manifestation(s) of anaphylaxis Syncope, hypotension Syncope, hypotension Syncope, hypotension, dyspnea
Skin prick test Vespula: Pos (2+) Vespula: Pos (3+) Vespula: Neg
Honey bee: Neg Honey bee: Neg Honey bee: Neg
ImmunoCap (normal value <0.35 kU/L) Vespula: 0.86 kE/L Vespula: 0.76 kE/L Vespula: <0.10 kE/L
Honey bee: <0.10 kE/L Honey bee: <0.10 kE/L Honey bee: <0.10 kE/L
Intracutaneous test n/a n/a Vespula: Pos (at 10-4 μg/ml
concentration) Honey bee: Neg
Serum total IgE (kE/L) 14 89 35
sBT (normal value <11.4 μg/L) 12 14 23
UP-like skin lesions None None None
Multifocal mast cell clusters None None None
>25% mast cells spindle- shaped or with
abnormal morphology




Kit mutation D816V + + -
Venom immunotherapy Yes, lifelong Yes, lifelong Planned for 5 years
Final diagnosis MMAS* SM# Non-clonal HVA¤
SM systemic mastocytosis, MMAS monoclonal mast cell activation syndrome, UP-like urticaria pigmentosa like, HVA hymenoptera venom allergy.
*MMAS diagnosis was established by fulfillment of mast cells clonality (abberant immunophenotype and/or proven c-kit mutation D816V.
#SM diagnosis was established by fulfillment of 3 minor criteria (presence of atypical mast cell morphology, abberant immunophenotype and Kit mutation D816V).
¤Non-clonal HVA diagnosis was established after excluding mast cells clonality and other histopathological features of bone marrow mast cells.
n/a, not analyzed; sBT Baseline serum tryptase.
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Evaluation of the above-mentioned cases exemplifies the
high stakes diagnostic challenge encountered by the
allergist. The patients presented with demographically
(age and gender), clinically and somewhat serologically
similar data, yet all three ended up with different diag-
noses. Diagnosis of anaphylaxis could be made clinically
by using NIH criteria, accordingly hypotension related
symptoms presented in all cases. We have considered
differential diagnosis such as hyperventilation, panic at-
tack/anxiety; however, these were unlikely in the clinical
context since there were a clear temporality in all in-
stances. Unfortunately, there were no tryptase analyses
from any of the cases during the acute reaction. There
were no alternative explanations of elevated baseline
tryptase levels in any of the patients since none of them
suffered from associated diseases, such as renal failure.
It is noteworthy that the absence of venom sensitization
by skin prick testing and/or ImmunoCap despite a convin-
cing history has been a well-known phenomenon in
mastocytosis patients with HVA [17,18]. In line with a
recent study [19], even performing a basophil activation
test (BAT) in the Case 3 did not provide any further
support for wasp or bee sensitization. Interestingly,when we performed ICT in this patient, we could finally
prove a wasp sensitization. Thus, all four tests (SPT,
ImmunoCAP, BAT and ICT) should be performed in
negative tested HVA patients before considering a pa-
tient as a true negative.
Patients with increased sBT (>11.4 μg/L) have a greater
risk to develop more severe anaphylactic reactions to hy-
menoptera stings compared to those with normal values
[20,21], and are also thought to have an increased risk for
the appearance of side-effects during venom immunother-
apy [22]. In Cases 1 and 2, fortunately both updosing and
maintenance venom immunotherapies have been toler-
ated without any side effects (follow-up of seven years and
three years respectively). Furthermore, the management of
HVA patients with CMD involves unusual problems in-
cluding severe, potentially fatal anaphylactic reactions
after new stings, even if patients undergo venom specific
immunotherapy [4,5]. The current guidelines, therefore,
recommend life-long immunotherapy for patients with
CMD, whereas 3–5 years venom immunotherapy induces
long-term protection in patients with HVA alone. Thus, it
is of immense importance to identify risk-prone patients
by investigating a possible underlying CMD in patients
with severe HVA.
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for patients with CMD; however, as demonstrated in this
study, sBT per se is not a sufficient marker to distinguish
different anaphylaxis phenotypes. Currently, the definite
diagnosis in such patients can only be established after a
bone marrow biopsy. Nevertheless, the identification of
high risk patients that could be eligible for bone marrow
examination remains a subject of discussion. According
to the current guidelines, a bone marrow biopsy in pa-
tients with HVA is recommended if sBT is higher than
20 μg/L, or when signs and symptoms of mastocytosis,
such as urticaria pigmentosa, are present [6]. Yet, 34% of
the patients with HVA and CMD have a sBT lower than
20 μg/L [3]. Therefore it has been proposed that the sBT
cut-off should be lowered to 11.4 μg/L to assess mast
cell clonality including histopathological evaluation of
bone marrow [22]. However, this practice has not yet
come under consideration as a standard routine. Inter-
estingly, the Spanish Network on Mastocytosis has re-
cently proposed a scoring method to prescreen HVA
patients before a possible further investigation with bone
marrow examination in order to determine underlying
CMD [23]. All three cases in our study scored enough to
qualify bone marrow examination supporting that
REMA-score could be beneficial tool in similar cases. In
Case 3, we considered the option to perform a new bone
marrow biopsy since the baseline tryptase levels remain
elevated. At the moment, however, the patient denied to
undergo a new biopsy.
The accurate diagnosis has both therapeutic and pre-
ventive implications for management strategies. Hence,
patients with anaphylactic shock after insect sting and
elevated sBT (>11.4 μg/L) might be considered for bone-
marrow investigation in order to obtain better risk assess-
ment regardless of other signs or symptoms of CMD.
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